{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T12:45:30Z","timestamp":1777293930084,"version":"3.51.4"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Department of Information Engineering, University of Padova","award":["SID 2020"],"award-info":[{"award-number":["SID 2020"]}]},{"name":"Department of Information Engineering, University of Padova","award":["SID 2020"],"award-info":[{"award-number":["SID 2020"]}]},{"DOI":"10.13039\/501100003500","name":"Universit\u00e0 degli Studi di Padova","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003500","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biol Direct"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Doxorubicin (DOXO) is a well-known chemotherapy drug, which is widely used in the treatment of Multiple Myeloma (MM), a treatable but not curable type of blood cancer. Here, we propose a pharmacokinetics and pharmacodynamics (PK\/PD) simulation environment, aimed at facilitating the optimization of DOXO treatment regimens in MM treatment. The resulting model has a transparent mechanistic structure, which facilitates its use and interpretation. The simulator was developed using a combination of experimental and modeling techniques, starting from <jats:italic>in vitro<\/jats:italic> PK\/PD experiments conducted on MM cells. In our previous work, we carefully developed a PK model for DOXO in MM cells by fitting experimental data. We now devise a PD model from <jats:italic>in vitro<\/jats:italic> data investigating the effect of different concentrations of DOXO on cell growth and death in MM cell populations. The PK model is extended to enable a clear mechanistic link between the PK and the PD models, hence providing a complete PK\/PD simulator. We show how the mathematical model can be exploited to simulate different DOXO administration protocols with different dosages, repetitions and exposure times, thus, making it possible to explore the effect of a wide range of treatment protocols easily.<\/jats:p>","DOI":"10.1186\/s13062-025-00626-x","type":"journal-article","created":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T14:42:31Z","timestamp":1742568151000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Doxorubicin PK\/PD modeling in multiple myeloma: towards in silico trials"],"prefix":"10.1186","volume":"20","author":[{"given":"Daniele","family":"Andrean","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesco","family":"Da Ros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario","family":"Mazzucato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morten Gram","family":"Pedersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Visentin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,21]]},"reference":[{"issue":"9412","key":"626_CR1","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S0140-6736(04)15736-X","volume":"363","author":"B Sirohi","year":"2004","unstructured":"Sirohi B, Powles R. Multiple myeloma. Lancet. 2004;363(9412):875\u201387. https:\/\/doi.org\/10.1016\/S0140-6736(04)15736-X.","journal-title":"Lancet"},{"issue":"6","key":"626_CR2","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","volume":"43","author":"D Kazandjian","year":"2016","unstructured":"Kazandjian D. Multiple myeloma epidemiology and survival: a unique malignancy. Seminars Oncol. 2016;43(6):676\u201381. https:\/\/doi.org\/10.1053\/j.seminoncol.2016.11.004.","journal-title":"Seminars Oncol"},{"issue":"5","key":"626_CR3","doi-asserted-by":"publisher","first-page":"e422","DOI":"10.1038\/bcj.2016.31","volume":"6","author":"PS Becker","year":"2016","unstructured":"Becker PS, Gooley TA, Green DJ, Burwick N, Kim TY, Kojouri K, et al. A phase 2 study of bortezomib, cyclophosphamide, pegylated liposomal doxorubicin and dexamethasone for newly diagnosed multiple myeloma. Blood Cancer J. 2016;6(5):e422\u2013e422. https:\/\/doi.org\/10.1038\/bcj.2016.31.","journal-title":"Blood Cancer J."},{"issue":"6","key":"626_CR4","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1093\/annonc\/mdn018","volume":"19","author":"A Palumbo","year":"2008","unstructured":"Palumbo A, Gay F, Bringhen S, Falcone A, Pescosta N, Callea V, et al. Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma. Annals Oncol. 2008;19(6):1160\u20135. https:\/\/doi.org\/10.1093\/annonc\/mdn018.","journal-title":"Annals Oncol"},{"issue":"2","key":"626_CR5","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1093\/jac\/dkp434","volume":"65","author":"J Gloede","year":"2010","unstructured":"Gloede J, Scheerans C, Derendorf H, Kloft C. In vitro pharmacodynamic models to determine the effect of antibacterial drugs. J Antimicrob Chemother. 2010;65(2):186\u2013201. https:\/\/doi.org\/10.1093\/jac\/dkp434.","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"626_CR6","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1016\/j.exphem.2007.06.016","volume":"35","author":"M Zlei","year":"2007","unstructured":"Zlei M, Egert S, Wider D, Ihorst G, W\u00e4sch R, Engelhardt M. Characterization of in vitro growth of multiple myeloma cells. Exp Hematol. 2007;35(10):1550\u201361. https:\/\/doi.org\/10.1016\/j.exphem.2007.06.016.","journal-title":"Exp Hematol"},{"issue":"5","key":"626_CR7","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1128\/AAC.03639-14","volume":"59","author":"TP Lim","year":"2015","unstructured":"Lim TP, Cai Y, Hong Y, Chan ECY, Suranthran S, Teo JQM, et al. In vitro pharmacodynamics of various antibiotics in combination against extensively drug-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother. 2015;59(5):2515\u201324. https:\/\/doi.org\/10.1128\/AAC.03639-14.","journal-title":"Antimicrob Agents Chemother"},{"issue":"15","key":"626_CR8","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.ifacol.2021.10.263","volume":"54","author":"M Fliess","year":"2021","unstructured":"Fliess M, Join C, Moussa K, Djouadi SM, Alsager MW. Toward simple in silico experiments for drugs administration in some cancer treatments. IFAC-PapersOnLine. 2021;54(15):245\u201350. https:\/\/doi.org\/10.1016\/j.ifacol.2021.10.263.","journal-title":"IFAC-PapersOnLine"},{"key":"626_CR9","doi-asserted-by":"publisher","first-page":"828701","DOI":"10.5402\/2012\/828701","volume":"2012","author":"Mallet DG Trisilowati","year":"2012","unstructured":"Trisilowati Mallet DG. In silico experimental modeling of cancer treatment. ISRN Oncol. 2012;2012:828701. https:\/\/doi.org\/10.5402\/2012\/828701.","journal-title":"ISRN Oncol"},{"issue":"1","key":"626_CR10","doi-asserted-by":"publisher","first-page":"5725","DOI":"10.1038\/s41598-017-05902-z","volume":"7","author":"MT McKenna","year":"2017","unstructured":"McKenna MT, Weis JA, Barnes SL, Tyson DR, Miga MI, Quaranta V, et al. A predictive mathematical modeling approach for the study of doxorubicin treatment in triple negative breast cancer. Sci Rep. 2017;7(1):5725. https:\/\/doi.org\/10.1038\/s41598-017-05902-z.","journal-title":"Sci Rep"},{"issue":"4","key":"626_CR11","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.3390\/jcm11041006","volume":"11","author":"M Ghita","year":"2022","unstructured":"Ghita M, Billiet C, Copot D, Verellen D, Ionescu CM. Model calibration of pharmacokinetic-pharmacodynamic lung tumour dynamics for anticancer therapies. J Clin Med. 2022;11(4):1006. https:\/\/doi.org\/10.3390\/jcm11041006.","journal-title":"J Clin Med"},{"key":"626_CR12","doi-asserted-by":"publisher","unstructured":"Doshmanziari R, Ros FD, Mazzucato M, Pedersen MG, Visentin R. Modeling Doxorubicin Pharmacokinetics in Multiple Myeloma Suggests Mechanism of Drug Resistance. IEEE Transactions on Biomedical Engineering. 2023;p. 1\u201310. https:\/\/doi.org\/10.1109\/TBME.2023.3324017.","DOI":"10.1109\/TBME.2023.3324017"},{"issue":"3","key":"626_CR13","first-page":"335","volume":"113","author":"RE Goldman-Leikin","year":"1989","unstructured":"Goldman-Leikin RE, Salwen HR, Herst C, Variakojis D, Bian ML, Le Beau MM, et al. Characterization of a novel myeloma cell line, MM. 1. The. J lab Clin Med. 1989;113(3):335\u201345.","journal-title":"J lab Clin Med"},{"key":"626_CR14","unstructured":"The MathWorks\u00a0Inc.: MATLAB version: 9.12.0.1975300 (R2022a) Update 3. Natick, Massachusetts, United States: The MathWorks Inc. Available from: https:\/\/www.mathworks.com."},{"issue":"3","key":"626_CR15","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/S1016-8478(23)13547-3","volume":"9","author":"C-H Choi","year":"1999","unstructured":"Choi C-H, Kim H-S, Rha H-S, Jeong J-H, Park Y-H, Min Y-D, et al. Drug Concentration-dependent expression of multidrug resistance-associated protein and P-glycoprotein in the doxorubicin-resistant acute myelogenous leukemia sublines. Mol Cells. 1999;9(3):314\u20139. https:\/\/doi.org\/10.1016\/S1016-8478(23)13547-3.","journal-title":"Mol Cells"},{"issue":"1","key":"626_CR16","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.cmpb.2007.07.002","volume":"88","author":"G Bellu","year":"2007","unstructured":"Bellu G, Saccomani MP, Audoly S, D\u2019Angi\u00f2 L. DAISY: a new software tool to test global identifiability of biological and physiological systems. Comput Methods Programs Biomed. 2007;88(1):52\u201361. https:\/\/doi.org\/10.1016\/j.cmpb.2007.07.002.","journal-title":"Comput Methods Programs Biomed"},{"issue":"3","key":"626_CR17","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1007\/BF00806343","volume":"65","author":"Y Yuanxi","year":"1991","unstructured":"Yuanxi Y. Robust bayesian estimation. Bulletin g\u00e9od\u00e9sique. 1991;65(3):145\u201350. https:\/\/doi.org\/10.1007\/BF00806343.","journal-title":"Bulletin g\u00e9od\u00e9sique."},{"key":"626_CR18","doi-asserted-by":"publisher","unstructured":"McDermott M, Eustace AJ, Busschots S, Breen L, Crown J, Clynes M, et\u00a0al. In vitro Development of Chemotherapy and Targeted Therapy Drug-Resistant Cancer Cell Lines: A Practical Guide with Case Studies. Frontiers in Oncology. 2014 Mar;4. https:\/\/doi.org\/10.3389\/fonc.2014.00040.","DOI":"10.3389\/fonc.2014.00040"}],"container-title":["Biology Direct"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13062-025-00626-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13062-025-00626-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13062-025-00626-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T14:42:43Z","timestamp":1742568163000},"score":1,"resource":{"primary":{"URL":"https:\/\/biologydirect.biomedcentral.com\/articles\/10.1186\/s13062-025-00626-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,21]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["626"],"URL":"https:\/\/doi.org\/10.1186\/s13062-025-00626-x","relation":{},"ISSN":["1745-6150"],"issn-type":[{"value":"1745-6150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,21]]},"assertion":[{"value":"5 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no Conflict of interest","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"33"}}